echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > TCR2 and Bristol-Myers Squibb form a partnership to evaluate mesothelin-positive solid tumor cell therapy

    TCR2 and Bristol-Myers Squibb form a partnership to evaluate mesothelin-positive solid tumor cell therapy

    • Last Update: 2021-12-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    TCR2 Therapeutics recently announced that it has reached a clinical trial cooperation agreement with Bristol-Myers Squibb (BMS) and plans to launch a phase 2 clinical trial to evaluate a new cell therapy gavocabtagene autoleucel (gavo-cel, TC-210) combined with anti-PD-1 therapy Opdivo (generic name: nivolumab, nivolumab) and anti-CTLA-4 therapy Yervoy (generic name: ipilimumab, ipilimumab), used for the treatment of refractory and mesothelial expression Solid tumors of mesothelin


    The main purpose of this phase 2 trial is to evaluate the efficacy of gavo-cel in patients with unresectable, metastatic or recurrent mesothelin-expressing solid tumors, including non-small cell lung cancer (NSCLC), ovarian cancer, and malignant pleura/peritoneum Mesothelioma (MPM) and cholangiocarcinoma


    The planned phase 2 clinical trial will evaluate the anti-tumor activity and better describe the safety of gavo-cel at the selected recommended phase 2 dose (RP2D)


    Among them, patients with NSCLC, ovarian cancer, and cholangiocarcinoma will receive the combined treatment of gavo-cel and Opdivo


    gavo-cel structure characteristics

    gavo-cel is a new type of TRuC (T cell receptor fusion construct) cell therapy, which consists of autologous genetically engineered T cells expressing a single domain antibody and CD3ε subunit fusion protein.


    Gavo-cel Phase 1 clinical trial data

    gavo-cel was developed for the treatment of mesothelin-positive solid tumors


    The phase 1/2 clinical trial of gavo-cel focuses on 4 indications: NSCLC, ovarian cancer, malignant pleural/peritoneal mesothelioma (MPM), and cholangiocarcinoma


    In the interim data of the dose escalation part of the phase 1/2 clinical trial, it has been confirmed that gavo-cel has consistent clinical benefits.


    Note: The original text has been deleted

    Original source: TCR2 Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid Tumors

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.